SPECT/CT superior to SPECT alone for imaging cardiac amyloidosis
SPECT/CT fusion imaging offers significant advantages over SPECT alone for imagin...Read more on AuntMinnie.comRelated Reading:
Fast acquisition techniques cut SPECT/CT bone scan times by half
SPECT/CT AI model predicts major adverse cardiac events
SPECT tracers go head-to-head in prostate cancer patients
SPECT/CT proves value over CT diagnosing renal cancer
Tc-99m SPECT/CT imaging detects COVID-19 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 10, 2023 Category: Radiology Source Type: news
General Pervez Musharraf, Former Pakistan President and Supporter of U.S. War on Terror, Dies at 79
General Pervez Musharraf, who seized power in a bloodless coup in Pakistan and supported the U.S. in the post 9/11 war on terror, died in Dubai on Feb. 5 after a long illness. He was 79. In June 2022, Musharraf’s family had revealed that he was suffering from amyloidosis, a rare disease that sees…#pervezmusharraf #pakistan #dubai #musharraf #pakistani #newdelhi #britishindia #karachi #istanbul #pakistanarmy (Source: Reuters: Health)
Source: Reuters: Health - February 5, 2023 Category: Consumer Health News Source Type: news
New ACC Guidance on Diagnosis, Management of Cardiac Amyloidosis New ACC Guidance on Diagnosis, Management of Cardiac Amyloidosis
The document provides a diagnostic algorithm and emphasizes the need for a multidisciplinary, individualized approach for this under-recognized cause of heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 26, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Bone Scintigraphy Can Help ID Cardiac Amyloidosis
TUESDAY, Jan. 17, 2023 -- For individuals undergoing bone scintigraphy, positive 99mTc-3,3- diphosphono-1,2-propanodicarboxylic-acid (99mTc-DPD), indicative of cardiac amyloidosis (CA), is associated with poor outcomes, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 17, 2023 Category: Pharmaceuticals Source Type: news
Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection
Under the multi-year strategic partnership, Anumana will conduct a clinical validation trial and seek FDA De Novo classification for the algorithm. (Source: mobihealthnews)
Source: mobihealthnews - December 15, 2022 Category: Information Technology Source Type: news
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI ™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™ (teclistamab-cqyv), a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and lenalidomide. According to the results, the immune-based triplet therapy regimen had a manageable safety profile with no unexpected safety signals observed. A very good partial response (VGPR) or better was achieved by 90.3 percent of patients with relapsed or refractory multiple ...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
CRISPR Gene Editing Takes Next Step in TTR Amyloidosis CRISPR Gene Editing Takes Next Step in TTR Amyloidosis
A phase 1 study showed robust responses in patients with TTR amyloidosis with cardiomyopathy, similar to those reported last year in amyloid polyneuropathy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 5, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Vutrisiran Receives EU Approval for hAATR Amyloidosis Vutrisiran Receives EU Approval for hAATR Amyloidosis
The RNAi therapeutic vutrisiran has been approved by the European Commission for hereditary transthyretin-mediated amyloidosis in adults with polyneuropathy on the basis of the phase 3 HELIOS-A trial.International Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 20, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
CRISPR infusion eliminates swelling in those with rare genetic disease
In a medical first, an infusion of the CRISPR gene editor into the blood of three people with a rare genetic disease is easing their symptoms, a biotech company reports. The experimental treatment tamped down a liver protein that causes painful and potentially life-threatening bouts of swelling in the throat and limbs. Two people in the company’s trial are doing so well after a single CRISPR injection that they no longer need drugs to control their condition.
The data were reported at a
meeting
today in Berlin on the disease, called hereditary angioedema. The effort marks the second time the company, Inte...
Source: ScienceNOW - September 16, 2022 Category: Science Source Type: news
Patisiran Benefits ATTR Amyloidosis With Cardiomyopathy: APOLLO-B Patisiran Benefits ATTR Amyloidosis With Cardiomyopathy: APOLLO-B
More details of the positive results with the RNAi therapeutic on functional capacity and quality of life were reported today.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 8, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
ASNC published new guide on hybrid imaging
The American Society of Nuclear Cardiology (ASNC) and three partner societie...Read more on AuntMinnie.comRelated Reading:
Aetna insurance to cover cardiac PET scans
Calnon named 2022 ASNC president
Groups ask NRC to allow virtual radiotracer training
ASNC, ASE win CMS recognition for ImageGuide Registry
ASNC releases directive on cardiac amyloidosis imaging (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 6, 2022 Category: Radiology Source Type: news
Mayo Clinic Q & amp;A podcast: Successful treatment of cardiac amyloidosis depends on early diagnosis
Cardiac amyloidosis is a type of amyloidosis, which occurs when the body produces abnormal proteins that bind together to form a substance called amyloid. Amyloids can deposit in any tissue or organ, including the heart, kidneys, liver and nerves. When amyloid collects in the heart muscle, it causes irreversible thickening of the heart wall and disrupts heart function. It reduces your heart's ability to fill with blood between heartbeats, resulting in less blood being pumped with… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 23, 2022 Category: Databases & Libraries Source Type: news
Positive Results for Patisiran in ATTR Amyloidosis Cardiomyopathy Positive Results for Patisiran in ATTR Amyloidosis Cardiomyopathy
The RNAi therapeutic patisiran improves functional capacity and quality of life in ATTR amyloidosis with cardiomyopathy, topline results of APOLLO-B show. The company will seek an FDA supplemental NDA.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 4, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
How Jennifer Doudna ’s Life Has Changed Since Discovering CRISPR 10 Years Ago
Jennifer Doudna was staring at a computer screen filled with a string of As, Cs, Ts, and Gs—the letters that make up human DNA—and witnessing a debilitating genetic disease being cured right before her eyes. Just a year earlier, in 2012, she and microbiologist Emmanuelle Charpentier had published a landmark paper describing CRISPR-Cas9, a molecular version of autocorrect for DNA, and she was seeing one the first demonstrations of CRISPR’s power to cure a human disease. She was in the lab of Dr. Kiran Musunuru, a Harvard researcher who was eager to show her the results from an experiment he had just finish...
Source: TIME: Health - July 1, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized feature Genetics healthscienceclimate Source Type: news
